




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/675, 31/44 // (A61K 31/675, 31:00) (A61K 31/44, 31:00)</p>	A1	<p>(11) International Publication Number: WO 97/49409</p> <p>(43) International Publication Date: 31 December 1997 (31.12.97)</p>
<p>(21) International Application Number: PCT/GB97/01722</p> <p>(22) International Filing Date: 24 June 1997 (24.06.97)</p> <p>(30) Priority Data: 9613182.6 24 June 1996 (24.06.96) GB</p> <p>(71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, N-0401 Oslo (NO).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KARLSSON, Jan, Olof, Gustav [SE/NO]; Solstua Terrasse 4, N-1450 Nesoddtangen (NO). JYNGE, Per [NO/NO]; Erling Skakkesgt 54, N-7013 Trondheim (NO). TOWART, Robertson [GB/GB]; 13 Sefton Paddock, Stoke Poges SL2 4PT (GB).</p> <p>(74) Agents: GOLDING, Louise et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	

(54) Title: CHELATING AGENTS AND THEIR METAL CHELATES FOR TREATING FREE RADICALS INDUCED CONDITIONS



(57) Abstract

The invention provides the use of a compound of formula (I) or a metal chelate or salt thereof in the manufacture of a therapeutic agent for use in the treatment or prophylaxis of conditions resulting from the presence of free radicals in the human or non-human animal body (wherein in formula (I): each R¹ independently represents hydrogen or -CH₂COR⁵; R⁵ represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; each R² independently represents a group XYR⁶; X represents a bond, or a C₁₋₃ alkylene or oxoalkylene group optionally substituted by a group R⁷; Y represents a bond, an oxygen atom or a group NR⁶; R⁶ is a hydrogen atom, a group COOR⁸, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more groups selected from COOR⁸, CONR⁸, NR⁸, OR⁸, =NR⁸, =O, OP(O) (OR⁸)R⁷ and OSO₃M; R⁷ is hydroxy, an optionally hydroxylated, optionally alkoxyalkyl or aminoalkyl group; R⁸ is a hydrogen atom or an optionally hydroxylated, optionally alkoxyalkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation; R³ represents a C₁₋₈ alkylene group, a 1,2-cycloalkylene group, or a 1,2-arylene group; and each R⁴ independently represents hydrogen or C₁₋₃ alkyl). Such compounds are particularly effective in relieving symptoms associated with reperfusion of ischemic tissue and in treating or preventing radiation-induced injury.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CHELATING AGENTS AND THEIR METAL CHELATES FOR TREATING FREE RADICALS INDUCED CONDITIONS

The present invention relates to the use of chelating agents and their metal chelates in medicine, in particular in treating conditions resulting from the presence of free radicals in the body, e.g. in the treatment of ischaemia-related diseases.

Short-lived but highly reactive free radicals have long been believed to be involved in various sorts of tissue damage, especially during reperfusion of ischaemic tissue and in radiation-induced injury. A key factor in the production of many free radicals is believed to be the availability of ferric ions which stimulate the formation of free radicals, such as hydroxyl, peroxy and hydroperoxy radicals, and singlet oxygen which cause membrane damage via lipid peroxidation.

Ischaemia-related diseases, in particular coronary artery diseases, account for the majority of deaths in Western countries. The reintroduction of oxygenated blood into ischaemic tissues can, in many cases, result in various forms of cardiac dysfunction, including arrhythmias, myocardial "stunning", arterial spasm and endothelial damage (Kirschner et al. J. Amer. College of Surgeons 179: 103-117 (1994)). Furthermore, inactivation of NO, believed to have cardioprotective effects, can occur (see e.g. Vegh et al. Br. J. Pharmacol. 107: 910-911 (1992) and Lefer et al. Circulation 88: 2337-2350 (1993)).

Recent studies suggest that reperfusion injuries are largely a result of the production of oxygen-derived free radicals during reoxygenation of the perfused tissues. This is particularly so not only during the introduction of blood and oxygen during the early reperfusion period, but also in the subsequent protracted period of inflammatory response in the

previously ischemic tissues.

It will be appreciated that there thus exists a continuing need for compounds which are able to treat or prevent conditions arising from the presence of free radicals in the body, in particular compounds which are able to prevent reperfusion injuries.

The medical use of chelating agents and their metal chelates is well established, for example in diagnostic techniques such as X-ray, magnetic resonance imaging (MRI), ultrasound imaging or scintigraphy. A wide variety of chelating agents and metal chelates are known or have been described.

Aminopoly (carboxylic acid or carboxylic acid derivative) chelating agents and their metal chelates are well known and are described for example in EP-A-299795, EP-A-71564, DE-A-3401052, EP-A-203962 and EP-A-436579.


Dipyridoxyl based chelating agents and their chelates with trivalent metals have been described by Taliaferro (Inorg. Chem. 23: 1183-1192 (1984)). The compound N,N'-dipyridoxyl ethylenediamine-N,N'-diacetic acid (PLED) has been evaluated as a chelating agent for the preparation of gallium or indium containing radiopharmaceuticals (see Green et al. Int. J. Nucl. Med. Biol, 12(5): 381-386 (1985)).

A number of PLED derivatives and analogues have also been described for use in MRI contrast media, in particular the chelating agent N,N'-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N'-diacetic acid (DPDP) and its manganese (II) chelate, Mn DPDP (see EP-A-290047 and EP-A-292761).

We have now found that certain chelating agents, in particular dipyridoxyl and aminopolycarboxylic acid based chelating agents, and their metal chelates are particularly effective in treating or preventing tissue damage caused by free radicals and which are capable of relieving symptoms associated with reperfusion of

ischaemic tissue.

In one aspect the invention provides the use of a compound of formula I



(I)

or a metal chelate or salt thereof in the manufacture of a therapeutic agent for use in the treatment or prophylaxis of conditions resulting from the presence of free radicals in the human or non-human animal body (wherein in formula I

each R^1 independently represents hydrogen or $-\text{CH}_2\text{COR}^5$;

R^5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido;

each R^2 independently represents a group XYR^6 ;

X represents a bond, or a C_{1-3} alkylene or oxoalkylene group optionally substituted by a group R^7 ;

Y represents a bond, an oxygen atom or a group NR^6 ;

R^6 is a hydrogen atom, a group COOR^8 , an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more groups selected from COOR^8 , CONR^8_2 , NR^8_2 , OR^8 , $=\text{NR}^8$, $=\text{O}$, $\text{OP}(\text{O})(\text{OR}^8)\text{R}^7$ and OSO_3M ;

R^7 is hydroxy, an optionally hydroxylated, optionally alkoxyalkyl or aminoalkyl group;

R^8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxyalkyl group;

M is a hydrogen atom or one equivalent of a physiologically tolerable cation, e.g. an alkali or alkaline earth cation, an ammonium ion or an organic

- 4 -

amine cation, such as a meglumine ion;

R³ represents a C₁₋₈ alkylene group, preferably a C₁₋₆, e.g. a C₂₋₄ alkylene group, a 1,2-cycloalkylene group, or a 1,2-arylene group; and

each R⁴ independently represents hydrogen or C₁₋₃ alkyl).

In another aspect the invention provides a method of treatment of the human or non-human animal body to combat or prevent conditions associated with the presence of free radicals in the body, said method comprising administering to said body a compound of formula I or a metal chelate or salt thereof.

Other chelators suitable for use in the method of the invention include the macrocyclic and more preferably linear or branched aminopolycarboxylic acid chelants of EP-A-299795, EP-A-71564, DE-A-3401052, EP-A-203962, EP-A-436579 and the phosphorus oxyacid analogs. Preferred chelating agents include amides of DTPA and EDTA in which the nitrogens of the amide groups may be substituted by one or more C₁₋₁₈ alkyl groups, e.g. DTPA.BMA and EDTA.BMA.

As used herein the terms "alkyl" and "alkylene" include both straight-chained and branched, saturated and unsaturated hydrocarbons. The term "1,2-cycloalkylene" includes both cis and trans cycloalkylene groups and alkyl substituted cycloalkylene groups having from 5-8 carbon atoms. The term "1,2-arylene" includes phenyl and naphthyl groups and alkyl substituted derivatives thereof having from 6 to 10 carbon atoms.

Unless otherwise specified, any alkyl, alkylene or alkenyl moiety may conveniently contain from 1 to 20, preferably 1-8, more preferably 1-6 and especially preferably 1-4 carbon atoms.

Cycloalkyl, aryl and aralkyl moieties may conveniently contain 3-18, preferably 5-12 and especially preferably 5-8 ring atoms. Aryl moieties

comprising phenyl or naphthyl groups are preferred. As aralkyl groups, phenyl C₁₋₃ alkyl, especially benzyl, are preferred.

Where groups may optionally be substituted by hydroxy groups, this may be monosubstitution or polysubstitution and, in the case of polysubstitution, alkoxy and/or hydroxy substituents may be carried by alkoxy substituents.

In formula I, R⁵ is preferably hydroxy, C₁₋₈ alkoxy, ethylene glycol, glycerol, amino or C₁₋₈ alkylamido. Preferably each group R¹ represents -CH₂COR⁵ in which R⁵ is hydroxy.

In the compounds of formula I, X is preferably a bond or a group selected from CH₂, (CH₂)₂, CO, CH₂CO, CH₂CH₂CO or CH₂COCH₂. Preferably, Y represents a bond.

The compounds of formula I may have the same or different R² groups on the two pyridyl rings and these may be attached at the same or different ring positions. However, it is especially preferred that substitution be at the 5- and 6-positions, most especially the 6-position, i.e. para to the hydroxy group. Compounds in which the R² groups are identical and identically located, e.g. 6,6', are especially preferred.

Preferred as groups R⁶ are mono- or poly(hydroxy or alkoxy) alkyl groups or a group of the formula OP(O)(OR⁶)R⁷.

R⁷ is preferably hydroxy or an unsubstituted alkyl or aminoalkyl group.

Particularly preferred identities for group R² include CHR⁷OCO(CH₂)_xPh and CHR⁷OCO(CH₂CO)_xPh (wherein x is 1 to 3), CHR⁷OCOBu^t, CH₂N(H)R^{6'}, CH₂N(R^{6'})₂, N(H)R^{6'}, N(R^{6'})₂, CH₂OH, CH₂OR^{6'}, COOR^{6'}, CON(H)R^{6'}, CON(R^{6'})₂ or OR^{6'} (where R^{6'} is a mono- or polyhydroxylated, preferably C₁₋₄, especially preferably C₁₋₃, alkyl group), (CH₂)_nCOOR^{7'} (wherein n is 1 to 6), COOR^{7'} (where R^{7'} is a C₁₋₄ alkyl, preferably C₁₋₃, especially preferably a methyl group), CH₂OSO₃⁻M, CH₂CH₂COOH, CH₂OP(O)(OH)(CH₂)₃NH₂, CH₂OP(O)(OH)CH₃

- 6 -

or $\text{CH}_2\text{OP}(\text{O})(\text{OH})_2$ group). Yet more preferably, R^2 represents a group of the formula $\text{CH}_2\text{OP}(\text{O})(\text{OH})_2$.

Compounds of formula I in which R^3 is ethylene and R^2 has any of the identities listed above are particularly preferred.

Preferred metal chelates of the compounds for use in the method of the invention are those in which the metal ions are selected from the alkali and alkaline earth metals and from those metals having an atomic number from 22-31, 42, 44 and 58-70 and more particularly chelates having a K_a in the range from 10^9 to 10^{25} , preferably 10^{10} to 10^{24} , more preferably 10^{11} to 10^{23} , e.g. 10^{12} to 10^{22} . Particularly preferred chelates are those with metals other than iron which have a K_a value smaller, preferably by a factor of at least 10^3 , than the K_a value of the corresponding iron (Fe^{3+}) chelate. Suitable ions include Na^+ , Mn^{2+} , Ca^{2+} , Zn^{2+} , Cu^{2+} , Cu^+ , Gd^{3+} and Mg^{2+} . Mn^{2+} is especially preferred.

As chelates of aminopolycarboxylic acids, Mn DTPA.BMA and Mn EDTA.BMA are particularly preferred for use in accordance with the invention.

More particularly preferred for use in accordance with the invention is the compound N,N'-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N'-diacetic acid or N,N'-bis(3-hydroxy-2-methyl-5-phosphonomethyl-4-pyridyl-methyl)-ethylenediamine-N,N'-diacetic acid (hereinafter referred to as DPDP) and the manganese (II) chelate, Mn(DPDP).

If not all of the labile hydrogens of the chelates are substituted by the complexed metal ion, biotolerability and/or solubility of the chelate may be increased by substituting the remaining labile hydrogen atoms with physiologically biocompatible cations of inorganic and/or organic bases or amino acids. Examples of suitable inorganic cations include Li^+ , K^+ , Na^+ and especially Ca^{2+} . Suitable organic cations include ammonium, substituted ammonium, ethanolamine,

- 7 -

diethanolamine, morpholine, glucamine, N,N,-dimethyl glucamine, lysine, arginine or ornithine.

The chelating agents and the metal chelates thereof for use in accordance with the invention are particularly effective in the treatment or prevention of reperfusion-induced injuries, such as arrhythmias and endothelial damage which may occur during thrombolytic treatment, after reperfusion in cardio-pulmonary bypass, percutaneous transluminal coronary angioplasty (PTCA), and in cardiac surgery, including cardiac transplantation. A preferred use of the compounds herein described is in reducing myocardial reperfusion injury, e.g. following myocardial infarction arising from severe or acute myocardial ischemia.

A further use of the compounds of the invention is in relation to organ transplantation, e.g. with cardiac, liver, kidney or brain transplants. In this regard, the compounds may be administered to the organ donor or recipient either prior to, during or subsequent to transplant surgery. A preferred use of the compounds is as an organ transplant solution in which organs may be stored prior to transplantation.

The compounds for use in accordance with the invention are also effective in treating or preventing pro-inflammatory disorders, particularly in treating or preventing radiation-induced injury, e.g. in radiotherapy.

The chelating agents and metal chelates for use in the method of the invention are effective if administered following reperfusion of ischemic tissue. However, such compounds are also effective to prevent reperfusion-induced injury, e.g. following myocardial ischemia, if administered after the onset of interruption in coronary blood flow but prior to the onset of reperfusion. As a result, the method of the invention is applicable not only to cases where myocardial ischemia is expected, e.g. during cardio-

pulmonary bypass, PTCA and in cardiac surgery, but also in cases where myocardial ischemia is not planned, e.g. during cardiac arrest and during thrombolysis. In this regard, the compounds herein described are particularly useful as an adjunct to thrombolysis.

Viewed from a further aspect the invention thus provides a pharmaceutical composition comprising a chelating agent according to the invention or a metal chelate or salt thereof, together with one or more thrombolytic agents, and at least one pharmaceutically acceptable carrier or excipient.

Viewed from a yet still further aspect the invention provides a pack containing a chelating agent according to the invention or a metal chelate or salt thereof and separately a thrombolytic agent for simultaneous, separate or sequential use during a thrombolytic procedure.

In another aspect the invention provides the use of a chelating agent according to the invention or a metal chelate or salt thereof together with one or more thrombolytic agents in the manufacture of a medicament for use during a thrombolytic procedure.

The invention further provides a method of treatment of a human or non-human animal body, said method comprising administering to said body an effective amount of a compound of formula I or a metal chelate or salt thereof, and a thrombolytic agent, simultaneously, separately or sequentially during a thrombolytic procedure.

Examples of thrombolytic agents suitable for use in accordance with the invention include aspirin, plasmin, prourokinase, streptokinase, tissue plasminogen activator, urokinase, hirudin and anti-platelet drugs.

The compounds of the invention may be prepared by methods known in the art. Suitable methods for preparing the amino polycarboxylic acid based chelating agents are described in EP-A-299795, EP-A-71564, DE-A-

3401052, EP-A-203962 and EP-A-436579.


In preparing the dipyridoxyl compounds, the compound PLED may be used as a starting material and may be appropriately derivatised using conventional procedures to obtain the compounds of formula I.

Suitable methods for preparing the compounds of formula I are described for example in EP-A-290047.

Alternatively the compounds of formula I may be prepared by reacting the corresponding pyridoxal compound with an alkylene diamine according to the procedure for making PLED described by Taliaferro (supra).

Alternatively, the compounds in accordance with the invention may be prepared by a process comprising one or more of the following steps:

(a) reacting a compound of formula II




with a diamine of formula (III)



(wherein R^3 and R^4 are as hereinbefore defined and $\text{R}^{2'}$ is an optionally protected group R^2 as hereinbefore defined)

(b) hydrogenating a compound of formula (IV) obtained in step (a)


- 10 -



(IV)

(wherein R^3 , R^4 and $R^{2'}$ are as hereinbefore defined)

(c) reacting a compound of formula (V)



(V)

(wherein R^3 , R^4 and $R^{2'}$ are as hereinbefore defined) with a haloacetic, preferably bromoacetic, acid, and if necessary removing any protecting groups used; and

(d) converting a compound of formula I into a chelate complex or salt thereof.

Pyridoxyl phosphate, pyridoxal and the other compounds of formula II and the alkylene diamine, cycloalkylene diamine and arylene compounds of formula III are well-known compounds readily available or can be readily synthesised by procedures well known in the art.

The reaction of step (a) may conveniently be performed in a suitable solvent, such as an alcohol (e.g. methanol) at a temperature in the range of from 0 to 60°C.

- 11 -

To obtain compounds of formula I where the R^2 groups are the same, a diamine of formula III may be reacted with two molar equivalents of a compound of formula II. For the preparation of compounds of formula I where the R^2 groups are different, the diamine of formula III is first reacted with a first compound of a formula II having a desired $R^{2'}$ group, and the reaction product thereby obtained is then reacted with a second compound of formula II bearing a different $R^{2'}$ group.

The hydrogenation of step (b) may be performed using conventional procedures, e.g. using a palladium or platinum catalyst.

The metal chelates for use in accordance with the invention may be formed by conventional procedures known in the art. In general, such processes involve dissolving or suspending a metal oxide or metal salt (e.g. nitrate, chloride or sulfate) in water or a lower alcohol such as methanol, ethanol, or isopropanol. To this solution or suspension is added an equimolar amount of the chelating agent in water or a lower alcohol and the mixture is stirred, if necessary with heating moderately or to the boiling point, until the reaction is completed. If the chelate salt formed is insoluble in the solvent used, the reaction product is isolated by filtering. If it is soluble, the reaction product is isolated by evaporating to dryness, e.g. by spray drying or lyophilising.

If acid groups such as the phosphoric acid groups are still present in the resulting chelate, it is advantageous to convert the acidic chelate salt into a neutral chelate salt by reaction with inorganic and/or organic bases or amino acids, which form physiologically acceptable cations, and to isolate them.

The carboxylic and phosphoric acid groups of the chelating agents can also be neutralised by esterification to prepare carboxylate and phosphate esters. Such esters can be prepared from the

corresponding alcohols by conventional procedures known in the art. Suitable esters include, for example, esters of straight-chained or branched alcohols having from 1 to 18 carbon atoms, mono and polyhydric alkyl amino alcohols having from 1 to 18 carbon atoms, preferably having from 1 to 6 carbons, such as serinol or diethanolamine, and polyhydric alcohols having from 1 to 18 carbon atoms, such as ethylene glycol or glycerol.

Where the metal chelate carries an overall charge it will conveniently be used in the form of a salt with a physiologically acceptable counterion, for example an ammonium, substituted ammonium, alkali metal or alkaline earth metal (e.g. calcium) cation or an anion deriving from an inorganic or organic acid. In this regard, meglumine salts are particularly preferred.

The therapeutic agents of the present invention may be formulated with conventional pharmaceutical or veterinary formulation aids, for example stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc. and may be in a form suitable for parenteral or enteral administration, for example injection or infusion or administration directly into a body cavity having an external escape duct, for example the gastrointestinal tract, the bladder or the uterus. Thus the agent of the present invention may be in a conventional pharmaceutical administration form such as a tablet, capsule, powder, solution, suspension, dispersion, syrup, suppository, etc. However, solutions, suspensions and dispersions in physiologically acceptable carrier media, for example water for injections, will generally be preferred.

The compounds according to the invention may therefore be formulated for administration using physiologically acceptable carriers or excipients in a manner well-known to those skilled in the art. For example, the compounds, optionally with the addition of pharmaceutically acceptable excipients, may be suspended

- 13 -

or dissolved in an aqueous medium, with the resulting solution or suspension then being sterilized. Suitable additives include, for example, physiologically biocompatible buffers (e.g. tromethamine hydrochloride), additions (e.g. 0.01 to 10 mole percent) of chelants (such as, for example, DTPA, DTPA-bisamide or non-complexed chelants of formula I) or calcium chelate complexes (e.g. calcium DTPA, CaNaDTPA-bisamide, calcium salts or chelates of chelants of formula I), or, optionally, additions (e.g. 1 to 50 mole percent) of calcium or sodium salts (e.g. calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate combined with metal chelate complexes of chelating agents according to the invention and the like).

If the compounds are to be formulated in suspension form, e.g., in water or physiological saline for oral administration, a small amount of soluble chelate may be mixed with one or more of the inactive ingredients traditionally present in oral solutions and/or surfactants and/or aromatics for flavouring.

The preferred mode for administering the metal chelates in accordance with the invention is parenteral, e.g. intravenous or intra-arterial administration. Parenterally administrable forms, e.g. intravenous solutions, should be sterile and free from physiologically unacceptable agents, and should have low osmolality to minimize irritation or other adverse effects upon administration, and thus the compositions should preferably be isotonic or slightly hypertonic. Suitable vehicles include aqueous vehicles customarily used for administering parenteral solutions such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection and other solutions such as are described in Remington's Pharmaceutical Sciences, 15th ed., Easton: Mack Publishing Co., pp. 1405-1412 and 1461-1487 (1975) and The National Formulary XIV, 14th

ed. Washington: American Pharmaceutical Association (1975). The solutions may contain preservatives, antimicrobial agents, buffers and antioxidants conventionally used for parenteral solutions, excipients and other additives which are compatible with the chelates and which will not interfere with the manufacture, storage or use of the products.

The therapeutic agent in accordance with the invention, if in solution, suspension or dispersion form, will generally contain the chelant or metal chelate at a concentration in the range of from 0.0001 to 5.0 moles per litre, preferably 0.01 to 0.1 moles per litre. If convenient, the therapeutic agent may however be supplied in a more concentrated form for dilution prior to administration.

The therapeutic agent in accordance with the invention may conveniently be administered in amounts of from 10^{-2} to 100 μmol of the compounds per kilogram of body weight, e.g. about 10 μmol per kg bodyweight.

The present invention will now be illustrated further by the following non-limiting Examples and with reference to the attached figures, in which:

Figure 1 illustrates changes in left ventricular developed pressure (LVDP) in rat hearts during hypoxia and reoxygenation in the presence of MnDPDP (30 μM). LVDP is expressed as a percentage of values obtained in the control period. Mean values \pm SD are shown. * indicates significant differences between the two groups ($p < 0.05$).

Figure 2 illustrates myocardial release of lactate dehydrogenase (LDH) in rat hearts during hypoxia and reoxygenation in the presence of MnDPDP (30 μM). LDH release is expressed in IU/ml. Mean values \pm SD are shown. * indicates significant differences between the two groups ($p < 0.05$).

Figure 3 shows the degree of infarction in pig hearts following treatment with NaCl.

- 15 -

Figure 4 shows the degree of infarction in pig hearts following treatment with MnDPDP.

EXAMPLE 1

The protective effect of MnDPDP against myocardial injury during hypoxia and reoxygenation was demonstrated *ex vivo*.

Method

Isolated rat hearts were perfused in the Langendorff mode at a constant flow rate (10 ml/min) at 37°C. The perfusion medium (glucose-containing Krebs Henseleit's bicarbonate buffer) was equilibrated with 95% O₂ + 5% CO₂ during normoxic conditions and with 95% N₂ + 5% CO₂ during hypoxia. Left ventricular (LV) developed pressure (LVDP), a main indicator of contractile function, was measured using a fluid-filled LV balloon connected to a pressure transducer and recording system. The coronary effluent was collected at intervals for the measurement of myocardial lactate dehydrogenase (LDH) release by a standard enzymatic technique.

The experimental time course (170 min) involved: control period 0-20 minutes (20 min normoxic perfusion); hypoxic period 20-140 minutes (120 min hypoxic perfusion); and reoxygenation period 140-170 minutes (30 min normoxic perfusion). Two experimental groups were studied: (a) MnDPDP group (n=3) with MnDPDP 30 μM present in the perfusate during the entire hypoxic period plus during the initial 10 minutes of reoxygenation; and (b) a non-treated control group (n=3).

Results

Figure 1 shows that LVDP, expressed as a percentage of values obtained in the control period, was from 15 to 40% higher with MnDPDP 30 μ M present during hypoxia and reoxygenation. Intergroup differences were significant at the end of hypoxia and during the first 5 minutes of reoxygenation.

Figure 2 shows that MnDPDP greatly reduced myocardial LDH release on reoxygenation. Maximal release (mean values \pm SD) after reintroduction of O₂ was 654 \pm 268 IU/min (third min) and 148 \pm 108 IU/min (second min) in the control and MnDPDP groups, respectively. Also the accumulated LDH release showed similar significant differences: 9505 \pm 3562 IU/30 min in control hearts, and 2887 \pm 1461 IU/min in MnDPDP treated hearts.

Improved contractile function during hypoxia and reoxygenation, and reduced enzyme leakage on reoxygenation is evidence of myocardial protection by MnDPDP 30 μ M during hypoxia plus reoxygenation.

EXAMPLE 2

Method:

Pigs were anaesthetized with sodium pentobarbitone 35 mg/kg intravenously (i.v.). After intubation a respirator was used to ventilate the animals with room air, if necessary supplemented with O₂ up to a total of 30%. Anaesthesia was maintained by continuous infusion of 0.5-5 mg/kg/hr Nembutal.

Thoracotomy was performed to expose the heart and the animals were catheterized for various haemodynamic measurements. A catheter was also placed in the jugular

- 17 -

vein for substance administration. Blood samples were taken at intervals during preparation for blood gas measurements (O_2 , CO_2).

After at least 30 minutes equilibration the pigs received 1.5 mg/kg i.v. lidocaine to reduce occlusion-induced arrhythmias. 10 minutes later the animals received 10 μ mol/kg MnDPDP or a corresponding volume of 0.9% NaCl (1 ml/kg). Thirty minutes later the left anterior descending branch of the left coronary artery (LAD) was occluded by two atraumatic vascular clamps.

Forty minutes later the LAD was reperfused by removal of the clamps. After another 120 minutes, the heart was removed, the coronary artery reoccluded, and the heart perfused with fluorescent microspheres to demonstrate the area at risk, i.e. the nonperfused area during occlusion. The ventricles were sliced into 8-9 slices. After tetrazolium staining the infarct size was measured and expressed as a percentage of area at risk.

Results:


Typical results are shown in Figures 3 and 4 attached hereto.

It can be seen that infarct size was larger in the 0.9% NaCl-treated animal (ca. 45% of area at risk) (Figure 3) than in the MnDPDP-treated animal (ca. 6% of area at risk) (Figure 4).

It is clear from Figures 3 and 4 that the manganese compound MnDPDP (mangafodipir), when injected into the animal before occlusion of LAD, unexpectedly protects the heart muscle from deleterious effects of occlusion-reperfusion.

Claims:

1. Use of a compound of formula I



(I)

or a metal chelate or salt thereof in the manufacture of a therapeutic agent for use in the treatment or prophylaxis of conditions resulting from the presence of free radicals in the human or non-human animal body (wherein in formula I

each R^1 independently represents hydrogen or $-CH_2COR^5$;

R^5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido;

each R^2 independently represents a group XYR^6 ;

X represents a bond, or a C_{1-3} alkylene or oxoalkylene group optionally substituted by a group R^7 ;

Y represents a bond, an oxygen atom or a group NR^6 ;

R^6 is a hydrogen atom, a group $COOR^8$, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more groups selected from $COOR^8$, $CONR^8$, NR^8 , OR^8 , $=NR^8$, $=O$, $OP(O)(OR^8)R^7$ and OSO_3M ;

R^7 is hydroxy, an optionally hydroxylated, optionally alkoxyalkyl or aminoalkyl group;

R^8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxyalkyl group;

M is a hydrogen atom or one equivalent of a physiologically tolerable cation;

- 19 -

R^3 represents a C_{1-8} alkylene group, a 1,2-cycloalkylene group, or a 1,2-arylene group; and each R^4 independently represents hydrogen or C_{1-3} alkyl).

2. Use as claimed in claim 1 wherein in formula I:

R^5 is hydroxy, C_{1-8} alkoxy, ethylene glycol, glycerol, amino or C_{1-8} alkylamido;

X is a bond or a group selected from CH_2 , $(CH_2)_2$, CO, CH_2CO , CH_2CH_2CO or CH_2COCH_2 ;

Y is a bond;

R^6 is a mono- or poly(hydroxy or alkoxy) alkyl group or a group of the formula $OP(O)(OR^8)R^7$; and

R^7 is hydroxy or an unsubstituted alkyl or aminoalkyl group.

3. Use as claimed in claim 1 or claim 2 wherein in formula I, R^3 is ethylene and each group R^1 represents $-CH_2COR^5$ in which R^5 is hydroxy.

4. Use as claimed in any one of claims 1 to 3 in which the compound of formula I is N,N'-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N'-diacetic acid.

5. Use as claimed in any preceding claim wherein said metal chelate comprises a metal ion selected from the alkali and alkaline earth metals and metals having an atomic number of from 22-31, 42, 44 and 58-70.

6. Use as claimed in claim 5 wherein said metal chelate has a K_a in the range of from 10^9 to 10^{25} .

7. Use as claimed in claim 5 wherein said metal chelate has a K_a in the range of from 10^{12} to 10^{22} .

8. Use as claimed in claim 5 wherein said metal chelate has a K_a value smaller by a factor of at least

- 20 -

10^3 than the K_a value of the corresponding iron (Fe^{3+}) chelate.

9. Use as claimed in any one of claims 5 to 8 wherein said metal ion is selected from Na^+ , Mn^{2+} , Ca^{2+} , Cu^+ , Cu^{2+} , Mg^{2+} , Gd^{3+} and Zn^{2+} .

10. Use as claimed in any preceding claim wherein said compound is the manganese (II) chelate of N,N'-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N'-diacetic acid.

11. Use as claimed in any preceding claim wherein said therapeutic agent is for use in the treatment or prophylaxis of a reperfusion-induced injury.

12. Use as claimed in claim 11 wherein said injury is a result of myocardial reperfusion.

13. Use as claimed in claim 11 wherein said injury is associated with a thrombolytic treatment, a cardiopulmonary bypass, percutaneous transluminal coronary angioplasty, or is a result of cardiac or transplantation surgery.

14. Use as claimed in any one of claims 1 to 10 wherein said therapeutic agent is for use in the treatment or prophylaxis of radiation-induced injury.

15. A pharmaceutical composition comprising a compound of formula I or a metal chelate or salt thereof as defined in any one of claims 1 to 10 together with a thrombolytic agent and at least one pharmaceutically acceptable carrier or excipient.

16. A pack containing a compound of formula I or a metal chelate or salt thereof as defined in any one of

- 21 -

claims 1 to 10 and separately a thrombolytic agent for simultaneous, separate or sequential use during a thrombolytic procedure.

17. Use of a compound of formula I or a metal chelate or salt thereof as defined in any one of claims 1 to 10 together with a thrombolytic agent in the manufacture of a medicament for use during a thrombolytic procedure.

18. A method of treatment of the human or non-human animal body to combat or prevent conditions associated with the presence of free radicals in the body, said method comprising administering to said body an effective amount of a compound of formula I or a metal chelate or salt thereof as defined in any one of claims 1 to 10.




FIG. 1.






FIG. 2.

3 / 4



normally perfused area 

area at risk (non perfused during occlusion)  + 

infarction 


ventricles 

FIG. 3.





FIG. 4.

INTERNATIONAL SEARCH REPORT

Inte. onal Application No
PCT/GB 97/01722

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K31/675 A61K31/44 //(A61K31/675,31:00),(A61K31/44,31:00)				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	ASPLUND: "Mangafodipir (mDPDP)- and MnCl ₂ -induced endothelium-dependent relaxation in bovine mesenteric arteries" J. PHARMACOL. EXP. THER., vol. 271, no. 2, 1994, pages 609-614, XP002043389	1-10		
Y	see the whole document ---	11,12,14		
Y	BRUROK: "Effects of manganese dipyridoxyl diphosphate, dipyridoxyl diphosphate-- , and manganese chloride on cardiac function. An experimental study in the Langendorff perfused rat heart" INVEST. RADIOL., vol. 30, no. 3, April 1995, pages 159-167, XP002043366 see the whole document ---	1-10		
-/--				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.				
<input checked="" type="checkbox"/> Patent family members are listed in annex.				
° Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family			
Date of the actual completion of the international search <div style="text-align: center; font-size: 1.2em;">13 October 1997</div>		Date of mailing of the international search report <div style="text-align: center; font-size: 1.2em;">24. 10. 97</div>		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-size: 1.2em;">Gac, G</div>		

INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/GB 97/01722

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PARAT ET AL.: "Does manganese protect cultured human skin fibroblasts against oxidative injury by UVA, dithranol and hydrogen peroxide ?" FREE RADICAL RESEARCH, vol. 20, no. 1, 1994, pages 339-351, XP002043390 see the whole document</p> <p style="text-align: center;">---</p>	1-10,14
Y	<p>WO 94 15925 A (MONSANTO COMPANY) 21 July 1994 see whole document, especially page 2, lines 20-27; page 40 lines 30-36 and page 41 lines 1-9</p> <p style="text-align: center;">---</p>	1-12,14
Y	<p>SORENSEN: "Essential metalloelement metabolism and radiation protection and recovery" RADIAT. RES., vol. 132, no. 1, 1992, pages 19-29, XP002043391 see page 19 see page 21 right column last paragraph see page 22 left column first and second paragraphs see page 24 - page 25</p> <p style="text-align: center;">---</p>	1,14
P,Y	<p>BRUROK: "Effects of MnDPDP, DPDP--, and MnCl2 on cardiac energy metabolism and manganese accumulation: an experimental study in the isolated perfused rat heart" INVEST. RADIOL., vol. 32, no. 4, April 1997, pages 205-211, XP002043392 see the whole document</p> <p style="text-align: center;">---</p>	1-10,14
A	<p>SAEED: "Occlusive and reperfused myocardial infarcts: differentiation with Mn-DPDP-enhanced MR imaging" RADIOLOGY, vol. 172, no. 1, 1989, pages 59-64, XP002043393 see the whole document</p> <p style="text-align: center;">---</p>	1-13,15, 17,18
A	<p>MISSELWITZ: "A toxicologic risk for using manganese complexes ? : a literature survey of existing data through several medical specialties" INVEST. RADIOL., vol. 30, no. 10, 1995, pages 611-620, XP002043394 see the whole document</p> <p style="text-align: center;">---</p>	1-10
	-/--	

1

INTERNATIONAL SEARCH REPORT

Int. Patent Application No

PCT/GB 97/01722

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PROCTOR: "free radicals and disease in man" PHYSIOL. CHEM. PHYSICS MED. NMR, vol. 6, no. 3, 1984, pages 175-195, XP002043395 see the whole document -----</p>	1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 97/01722

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT68 97 01722

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claim 18 is directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 97/01722

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9415925 A	21-07-94	AT 157090 T	15-09-97
		AU 5964894 A	15-08-94
		CA 2151262 A	21-07-94
		DE 69405086 D	25-09-97
		EP 0679155 A	02-11-95
		JP 8505622 T	18-06-96
